NYSE · IDXX
Healthcare · Medical - Diagnostics & Research
$575.98
Down-$24.77 (-4.30%)
Updated Oct 30, 2026, 11:28 PM
SID Score
5.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance · IDXX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
IDXX closed at $575.98 after 21 trading sessions, up 11.25% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $570.17 | $576.17 | $568.01 | $575.98 | 479.54K |
| Oct 28, 2026 | $556.78 | $567.77 | $555.2084 | $562.91 | 351.84K |
| Oct 27, 2026 | $563.23 | $567.545 | $559.0301 | $561.25 | 488.99K |
| Oct 26, 2026 | $564.23 | $571.75 | $557.94 | $570.21 | 528.16K |
| Oct 23, 2026 | $564.80 | $569.555 | $558.29 | $560.38 | 398.28K |
| Oct 22, 2026 | $562.01 | $568.67 | $558.39 | $566.76 | 430.12K |
| Oct 21, 2026 | $549.698 | $560.63 | $547.48 | $553.48 | 406.66K |
| Oct 20, 2026 | $559.14 | $561.83 | $552.78 | $557.93 | 439.77K |
| Oct 19, 2026 | $559.28 | $563.95 | $553.5202 | $555.80 | 497.1K |
| Oct 16, 2026 | $553.60 | $566.545 | $552.62 | $560.36 | 708.92K |
| Oct 15, 2026 | $538.34 | $547.83 | $535.285 | $547.18 | 545.29K |
| Oct 14, 2026 | $520.20 | $529.63 | $518.835 | $529.01 | 824.67K |
| Oct 13, 2026 | $525.73 | $528.485 | $514.725 | $520.31 | 446.34K |
| Oct 12, 2026 | $518.00 | $525.76 | $515.1299 | $523.94 | 552.79K |
| Oct 9, 2026 | $513.67 | $522.02 | $513.10 | $518.00 | 466.78K |
| Oct 8, 2026 | $506.67 | $514.51 | $506.12 | $513.14 | 696.68K |
| Oct 7, 2026 | $513.31 | $515.17 | $501.17 | $506.67 | 716.45K |
| Oct 6, 2026 | $529.14 | $531.38 | $512.54 | $515.41 | 502.36K |
| Oct 5, 2026 | $516.57 | $528.69 | $513.48 | $527.07 | 588.92K |
| Oct 2, 2026 | $523.50 | $524.02 | $516.02 | $518.39 | 288.82K |
| Oct 1, 2026 | $521.58 | $525.96 | $517.06 | $517.75 | 320.31K |
The latest Smart Investors Daily articles mentioning IDXX.
Company
Market Activity
Research & News
IDXX research
Company profile and research snapshot.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 27, 2026 | UBS | Neutral | — |
| Oct 16, 2026 | JP Morgan | Overweight | — |
| Oct 12, 2026 | Keybanc | Sector Weight | — |
| Aug 11, 2026 | Barclays | Overweight | — |
| Aug 5, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
Yahoo · Oct 22, 2026
Is IDXX a good stock to buy? We came across a bullish thesis on IDEXX Laboratories, Inc. on Astute Optics – US’s Substack. In this article, we will summarize the bulls’ thesis on IDXX. IDEXX Laboratories, Inc.’s share was trading at $553.48 as of October 21st 2026. IDXX’s trailing and forward P/E were 36.65 and 31.45 respectively […]
Yahoo · Oct 21, 2026
IDEXX Laboratories (IDXX) drew fresh attention after Jefferies reiterated its Buy rating while cutting two animal health peers on pricing concerns, and highlighted diagnostics as relatively better insulated within the broader veterinary and livestock market. Recent trading has shifted in IDEXX Laboratories' favor, with a 7 day share price return of 5.47% and a 30 day share price gain of 8.27%. However, the year to date share price return is down 16.73% and the 1 year total shareholder return...
Yahoo · Oct 20, 2026
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Yahoo · Oct 19, 2026
Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IDXX.
